Cargando…
Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells
Mitochondrial dysfunction plays a primary role in neurodevelopmental anomalies and neurodegeneration of Down syndrome (DS) subjects. For this reason, targeting mitochondrial key genes, such as PGC-1α/PPARGC1A, is emerging as a good therapeutic approach to attenuate cognitive disability in DS. After...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609571/ https://www.ncbi.nlm.nih.gov/pubmed/31316549 http://dx.doi.org/10.3389/fgene.2019.00606 |
_version_ | 1783432334489419776 |
---|---|
author | Mollo, Nunzia Nitti, Maria Zerillo, Lucrezia Faicchia, Deriggio Micillo, Teresa Accarino, Rossella Secondo, Agnese Petrozziello, Tiziana Calì, Gaetano Cicatiello, Rita Bonfiglio, Ferdinando Sarnataro, Viviana Genesio, Rita Izzo, Antonella Pinton, Paolo Matarese, Giuseppe Paladino, Simona Conti, Anna Nitsch, Lucio |
author_facet | Mollo, Nunzia Nitti, Maria Zerillo, Lucrezia Faicchia, Deriggio Micillo, Teresa Accarino, Rossella Secondo, Agnese Petrozziello, Tiziana Calì, Gaetano Cicatiello, Rita Bonfiglio, Ferdinando Sarnataro, Viviana Genesio, Rita Izzo, Antonella Pinton, Paolo Matarese, Giuseppe Paladino, Simona Conti, Anna Nitsch, Lucio |
author_sort | Mollo, Nunzia |
collection | PubMed |
description | Mitochondrial dysfunction plays a primary role in neurodevelopmental anomalies and neurodegeneration of Down syndrome (DS) subjects. For this reason, targeting mitochondrial key genes, such as PGC-1α/PPARGC1A, is emerging as a good therapeutic approach to attenuate cognitive disability in DS. After demonstrating the efficacy of the biguanide metformin (a PGC-1α activator) in a cell model of DS, we extended the study to other molecules that regulate the PGC-1α pathway acting on PPAR genes. We, therefore, treated trisomic fetal fibroblasts with different doses of pioglitazone (PGZ) and evaluated the effects on mitochondrial dynamics and function. Treatment with PGZ significantly increased mRNA and protein levels of PGC-1α. Mitochondrial network was fully restored by PGZ administration affecting the fission-fusion mitochondrial machinery. Specifically, optic atrophy 1 (OPA1) and mitofusin 1 (MFN1) were upregulated while dynamin-related protein 1 (DRP1) was downregulated. These effects, together with a significant increase of basal ATP content and oxygen consumption rate, and a significant decrease of reactive oxygen species (ROS) production, provide strong evidence of an overall improvement of mitochondria bioenergetics in trisomic cells. In conclusion, we demonstrate that PGZ is able to improve mitochondrial phenotype even at low concentrations (0.5 μM). We also speculate that a combination of drugs that target mitochondrial function might be advantageous, offering potentially higher efficacy and lower individual drug dosage. |
format | Online Article Text |
id | pubmed-6609571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66095712019-07-17 Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells Mollo, Nunzia Nitti, Maria Zerillo, Lucrezia Faicchia, Deriggio Micillo, Teresa Accarino, Rossella Secondo, Agnese Petrozziello, Tiziana Calì, Gaetano Cicatiello, Rita Bonfiglio, Ferdinando Sarnataro, Viviana Genesio, Rita Izzo, Antonella Pinton, Paolo Matarese, Giuseppe Paladino, Simona Conti, Anna Nitsch, Lucio Front Genet Genetics Mitochondrial dysfunction plays a primary role in neurodevelopmental anomalies and neurodegeneration of Down syndrome (DS) subjects. For this reason, targeting mitochondrial key genes, such as PGC-1α/PPARGC1A, is emerging as a good therapeutic approach to attenuate cognitive disability in DS. After demonstrating the efficacy of the biguanide metformin (a PGC-1α activator) in a cell model of DS, we extended the study to other molecules that regulate the PGC-1α pathway acting on PPAR genes. We, therefore, treated trisomic fetal fibroblasts with different doses of pioglitazone (PGZ) and evaluated the effects on mitochondrial dynamics and function. Treatment with PGZ significantly increased mRNA and protein levels of PGC-1α. Mitochondrial network was fully restored by PGZ administration affecting the fission-fusion mitochondrial machinery. Specifically, optic atrophy 1 (OPA1) and mitofusin 1 (MFN1) were upregulated while dynamin-related protein 1 (DRP1) was downregulated. These effects, together with a significant increase of basal ATP content and oxygen consumption rate, and a significant decrease of reactive oxygen species (ROS) production, provide strong evidence of an overall improvement of mitochondria bioenergetics in trisomic cells. In conclusion, we demonstrate that PGZ is able to improve mitochondrial phenotype even at low concentrations (0.5 μM). We also speculate that a combination of drugs that target mitochondrial function might be advantageous, offering potentially higher efficacy and lower individual drug dosage. Frontiers Media S.A. 2019-06-28 /pmc/articles/PMC6609571/ /pubmed/31316549 http://dx.doi.org/10.3389/fgene.2019.00606 Text en Copyright © 2019 Mollo, Nitti, Zerillo, Faicchia, Micillo, Accarino, Secondo, Petrozziello, Calì, Cicatiello, Bonfiglio, Sarnataro, Genesio, Izzo, Pinton, Matarese, Paladino, Conti and Nitsch http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Mollo, Nunzia Nitti, Maria Zerillo, Lucrezia Faicchia, Deriggio Micillo, Teresa Accarino, Rossella Secondo, Agnese Petrozziello, Tiziana Calì, Gaetano Cicatiello, Rita Bonfiglio, Ferdinando Sarnataro, Viviana Genesio, Rita Izzo, Antonella Pinton, Paolo Matarese, Giuseppe Paladino, Simona Conti, Anna Nitsch, Lucio Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells |
title | Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells |
title_full | Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells |
title_fullStr | Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells |
title_full_unstemmed | Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells |
title_short | Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells |
title_sort | pioglitazone improves mitochondrial organization and bioenergetics in down syndrome cells |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609571/ https://www.ncbi.nlm.nih.gov/pubmed/31316549 http://dx.doi.org/10.3389/fgene.2019.00606 |
work_keys_str_mv | AT mollonunzia pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT nittimaria pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT zerillolucrezia pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT faicchiaderiggio pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT micilloteresa pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT accarinorossella pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT secondoagnese pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT petrozziellotiziana pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT caligaetano pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT cicatiellorita pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT bonfiglioferdinando pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT sarnataroviviana pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT genesiorita pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT izzoantonella pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT pintonpaolo pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT mataresegiuseppe pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT paladinosimona pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT contianna pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells AT nitschlucio pioglitazoneimprovesmitochondrialorganizationandbioenergeticsindownsyndromecells |